Foresite’s immunology play gets a $200M megaround for TYK2 program, rebranding as Alumis

A Foresite-incubated biotech that debuted just eight months ago closed a new mega financing round on Thursday, and with it comes a company rebranding.

Esker Therapeutics will now call itself Alumis following the completion of a $200 million Series B, the biotech announced Thursday. The funds are expected to go...

Click to view original post